IPP Bureau
Caplin Point gets Colombia approval for Softgel Capsules
By IPP Bureau - May 07, 2024
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility
By IPP Bureau - May 07, 2024
With this, for all our USFDA facilities, EIRs are in place
Lupin receives USFDA approval for travoprost ophthalmic solution
By IPP Bureau - May 07, 2024
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr
By IPP Bureau - May 07, 2024
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US
By IPP Bureau - May 06, 2024
ORACEA is a trademark of Galderma Holdings, S.A.
Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
By IPP Bureau - May 06, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Amrutanjan Health Care to set up Rs. 132 crore plant for sanitary napkins
By IPP Bureau - May 06, 2024
The project funding will be done through a mix of internal accruals and debts.
Zydus Wellness launches pilot for ready-to-drink beverage Glucon-D Activors
By IPP Bureau - May 06, 2024
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr
By IPP Bureau - May 06, 2024
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs
By IPP Bureau - May 04, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr
By IPP Bureau - May 04, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
Wipro to implement Independent Health’s Medicare prescription payment plan platform
By IPP Bureau - May 04, 2024
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
By IPP Bureau - May 04, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake
By IPP Bureau - May 03, 2024
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
RPG Life Sciences posts Q4 FY24 PAT at Rs. 13.24 Cr
By IPP Bureau - May 03, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
